Robert L. Coleman, MD, FACOG, FACS

The panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.

Robert Coleman, MD, FACOG, FACS, reviews data from a study investigating combination letrozole plus ribociclib in patients with low-grade serous ovarian cancer.

Drs Eskander and Lewin discuss the sequencing immune checkpoint inhibitors for women with recurrent endometrial cancer.

Sharyn Lewin, MD, FACS, shares how she discusses side effects with patients receiving immune checkpoint inhibitors for advanced/recurrent endometrial cancer.

Experts explain what they are looking forward to in the future of treatment for patients with ER/PR+ and P53 wild-type or mutated advanced/recurrent endometrial cancer.

The panel discusses their opinions on the use of immunotherapy in different populations of women with advanced/recurrent endometrial cancer.

Ramez Eskander, MD, presents data from the GY018 study investigating pembrolizumab versus placebo in addition to carboplatin/paclitaxel in patients with advanced/recurrent endometrial cancer.

Dr Robert Coleman details data from the RUBY trial investing the role of checkpoint inhibitor dostarlimab in combination with chemotherapy for the treatment of advanced/recurrent endometrial cancer.

Drs Sharyn Lewin and Ramez Eskander share their thoughts on comprehensive molecular testing for all women with endometrial cancer.

Robert Coleman, MD, FACOG, FACS, reviews data from a study investigation the frequency of molecular testing in patients with endometrial cancer.

“Even in well-resourced countries, there are disparities in exposure to treatments; some of these are rooted deeply in social determinants of health and represent a very complex problem of providing equal access.”

The US Oncology expert looks back on how far the ovarian cancer treatment space has come, and where it is headed.

The US Oncology expert noted that input of the multidisciplinary board is a great place to air out concerns regarding ovarian cancer treatment.

The US Oncology expert explained that results from 2 trials presented at the 2020 ASCO Virtual Program may change how oncologists choose to treat these patients.

The US Oncology expert reported that secondary surgical cytoreduction may not lead to improved outcomes in women platinum-sensitive, recurrent ovarian cancer.

The expert discussed study methods from the NRG Oncology/Gynecologic Oncology Group (GOG) study presented at the 2020 ASCO Virtual Program.